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body weight with trough level monitoring for the prevention
of aGVHD in CBT recipients is strongly indicated.435
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Purpose: To determine the impact of Prosthetic Replacement
of the Ocular Surface Ecosystem (PROSE) treatment at ﬁve
years in patients with Ocular Graft versus Host Disease
(oGVHD).
Methods: All oGVHD patients seen in consultation for PROSE
treatment from 1/1/2008 e 6/30/2008 were identiﬁed
through billing records. Retrospective review of medical re-
cords, manufacturing data, and 5 year quality data was
undertaken.
Results: This 2008 oGVHD cohort was comprised of 21 pa-
tients. As of July 2013, the conclusion of the follow-up period,
6 patients were deceased and excluded from subsequent
analysis. One patient was not a candidate for PROSE treat-
ment due to not completing the training process, leaving 14
patients who were dispensed devices. After ﬁve years,
continued device wear was conﬁrmed in 10 of these 14 (71%)
patients. Discontinuation of wear was conﬁrmed in 3/14
(21%) patients. We could not ascertain wearing statusin the
remaining 1 (7%) patients. Likelihood of continued device
wear at ﬁve years is not dependent on age, sex, general
health status or proximity of residence to our clinic (p>0.05,
for each mean, by unpaired t-test). Reasons for discontinu-
ation of wear are reported. NEI VFQ-25 composite score
increased for patients wearing PROSE devices at 6 months
(D¼+26 points, p<0.001, mean¼85) with no signiﬁcant
decline after ﬁve years (D ¼-3 points, p¼0.73).
Conclusions: PROSE treatment offers continued beneﬁt, as
deﬁned by continued device wear and visual functioning at 5
years, to the majority of oGVHD candidates who were
dispensed devices. PROSE treatment is characterized by
long-term success in the management of Ocular Graft Versus
Host Disease.436
Sclerodermatous Chronic Gvhd in Patients Receiving
Tyrosine Kinase Inhibitors after Allogeneic
Hematopoeitic Stem Cell Transplant
Amandeep Salhotra 1, Joycelynne Palmer 2, Ni-Chun Tsai 3,
Tanya Paris 4, Pablo M. Parker 5, Stephen J. Forman 6,
Ryotaro Nakamura 7. 1 Hematology/Hematopoietic Cell
Transplant, City of Hope, Duarte, CA; 2 Information Sciences,
City of Hope, Duarte, CA; 3 Division of
BiostatisticsINFORMATION SCIENCES, City Of Hope, Duarte, CA;
4 Division of Biostatistics and Information sciences, City of
Hope, Duarte, CA; 5 City of Hope National Med Ctr, Duarte, CA;
6Hematology/Hematopoietic Cell Transplant, City of Hope
National Medical Center, Duarte, CA; 7Hematology/
Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
Background: Sclerodermatous GVHD (sclerosis) is seen in
approximately 20% of patients who received initial systemic
treatment for chronic GVHD after allogeneic HCT (Inamoto et
al. Blood 2013). Published reports suggest up regulation ofPDGFR (platelet derived growth factor receptor) and TGF-b
(transforming growth factor-b) pathways in patients with
sclerosis. Both pathways are subject to inhibition by imatinib.
We probed our database to explore if TKI use post HCT, will
reduce the incidence of sclerosis in patients with CML and
Ph+ALL.
Methods: Eighty-nine consecutive patients with CML (n¼41)
or Ph+ALL (n¼48) who underwent allogeneic HCT between
2005 to 2010 were included for analysis. Average age for
transplant was 44 years (range 18-62) All patients received
GCSF-mobilized PBSC from sibling (n¼49) or unrelated do-
nors (n¼40). A majority of our patients (n¼74) received fully
myeloablative conditioning regimens (FTBI with Cytoxan or
VP-16: n¼56, TMLI based regimens n¼3, and Bu/Cy: n¼15)
while the remaining 15 patients received reduced intensity
conditioning (Flu/Mel: n¼14, Clo/Mel: n¼1). Post transplant
GVHD prophylaxis was with sirolimus/tacrolimus in 53
(60%), tacrolimus/MTX in 13 (15%), and tacrolimus/sirolimus/
MTX in 11 (12%) patients. Median follow up duration was 30
months (Range 0.03-84.8 months).
Results: 55 patients (62%) received TKI therapy post trans-
plant while 34 patients (38%) did not receive TKI due to-
cytopenias (45%), TKI intolerance or resistance (27%), GVHD
(9%), infections (6%), and/or LFT abnormalities (6%). Median
time to start TKI post-transplant was 1.9 months (range: 0.7
e 17.9 months). The median duration of TKI therapy was 9.1
months (range 0.1- 89.4 months). Thirteen of 59 surviving
patients are currently on TKI therapy at last follow up.
The cumulative incidence of grade II-IV acute GVHD in
this patient cohort was 47% (Grade III/IV: 17%). The incidence
of chronic GVHD in the entire group was 76% (limited: n¼6,
extensive: n¼62). Eight of 55 patients exposed to TKI therapy
post transplant developed sclerosis with the median onset
time of 13.8 months (range 10.3-33.1 months). Sclerosis
occurred in 5 patients during TKI therapy whereas 3 patients
developed sclerosis after discontinuation of TKI. Seven of 34
patients who did not receive TKI post-HCT developed scle-
rosis with median onset of 17.1 months (range 6.7-53.7
months). The 2-year cumulative incidence of sclerosis was
9.2% (CI: 3.9-21.2%) for the TKI exposed group and 14.8% (CI:
6.6-33.4%) in the non-TKI group (p ¼0.69).
Conclusions: To our knowledge, this is the ﬁrst cohort study
to describe the incidence of sclerosis in patients who
received TKI post-HCT. The incidence of sclerosis appeared
consistent with the reported rate in the literature. At the
power for this analysis, statistical signiﬁcance- favoring TKI
use post HCT to reduce incidence of sclerotic cGVHD, was not
achieved.437
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